

Cancerfondens planeringsgrupp för Onkologisk radionuklidterapi
The planning group for Oncological radionuclide therapy
 – supported by The Swedish Cancer Society

SCIENTIFIC PROGRAM FOR THE ONLINE MEETING ON ZOOM 8th - 10th JUNE 2021
 Organized by Thuy Tran, Lovisa Lundholm, Kristina Viktorsson, Eva Forssell-Aronsson and Charlotte Andersson

Register for the meeting at radionuklidterapi.se

Zoom link to test your presentation 7th - 10th June

<https://stockholmuniversitet.zoom.us/j/62750422769>

Tue 08th June 2021	13.30 – 17.00 Zoom link: https://stockholmuniversitet.zoom.us/j/62820645913
13.30	ZOOM OPENING – CHECK-IN
14.00 – 14.10	WELCOME TO THE MEETING Thuy Tran – Karolinska Institutet Eva Forssell-Aronsson – University of Gothenburg
14.10 – 14.45	Early phase clinical studies of radiopharmaceuticals – what is needed? Qualified Person (QP), MSc Pharm Carsten Steiger, Karolinska University Hospital
14.45 – 14.50	Biobreak
SESSION 1	Moderator: Michael Ljungberg - Lund University
14.50 ABS 1	Iodine avidity in papillary thyroid cancer is associated with thyroglobulin expression, tissue proliferation and histological variant Joachim Nilsson – Karolinska University Hospital and Karolinska Institutet
15.05 ABS 2	A comparison and improvements of small VOI method for kidney absorbed dose measures in patients undergoing ¹⁷⁷ Lu-DOTATATE Jehangir Khan – University of Gothenburg
15.20 ABS 3	Changes in tumour dosimetric quantities over treatment cycles in [¹⁷⁷ Lu]Lu-DOTATATE therapy Johan Gustafsson – Lund University
15.35 ABS 4	A Phase II trial of ¹⁷⁷ Lu-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma, LuDO-N Jakob Stenman – Karolinska University Hospital and Karolinska Institutet
15.50 – 15.55	Biobreak
SESSION 2	Moderator: Annelie Lindström - Linköping University
15.55 ABS 5	Phase I evaluation of ^{99m} Tc-labelled HER2-binding DARPIn G3 Vladimir Tolmachev – Uppsala University
16.10 ABS 6	Development of novel Immuno-theranostic compounds targeting Leucine-Rich Repeat-Containing protein 15 (LRRC15), a TGFβ-driven pan-cancer biomarker. Mohamed Altai – Lund University
16.25 ABS 7	Bone marrow dosimetry S values for terbium-161 show increased source distribution dependency compared to lutetium-177 Jens Hemmingsson – University of Gothenburg
16.40 ABS 8	Translation of the GRPR antagonist [^{99m} Tc]Tc-maSSS-PEG2-RM26 in clinics for imaging of prostate tumors Ayman Abouzayed – Uppsala University
16.55 – 17.00	CLOSING FIRST DAY

WED 09th June 2021	12.30 – 17.00 Zoom link: https://stockholmuniversity.zoom.us/j/62820645913
12.30 SESSION 3	ZOOM LINK OPENING – CHECK-IN RAPID FIRE Moderator: Marika Nestor – Uppsala University
13.00 ABS 9	Fusion of breast cancer cells and macrophages is a spontaneous biological process that can be influenced by ionizing radiation Annelie Lindström – Linköping University
13.10 ABS 10	Mechanistic insights from high resolution DNA damage analysis to understand mixed high and low LET radiation exposure and its therapeutic potential Lovisa Lundholm – Stockholm University
13.20 ABS 11	Evaluation of the antioxidant α 1-microglobulin (A1M) as a kidney radioprotector in mouse models Amanda Kristiansson – Lund University
13.30 ABS 12	Early response in expression of radiation related proteins in mouse kidney after injection of ^{177}Lu -octreotate with or without recombinant α 1-microglobulin Charlotte Andersson – University of Gothenburg
13.40 – 13.50	Short break
SESSION 4	RAPID FIRE Moderator: Stig Palm – University of Gothenburg
13.50 ABS 13	Radionuclide Therapy Using ^{177}Lu -labeled ABD-fused ADAPT6 Scaffold Protein Javad Garousi – KTH
14.00 ABS 14	In vitro characterizations of ^{177}Lu -anti-CEA antibody and HSP90 inhibition for potentiated radioimmunotherapy of gastrointestinal cancer Tabassom Mohajer Shojai – Uppsala University
14.10 ABS 15	A conjugation strategy to modulate antigen binding as well as FcRn interaction lead to improved tumor targeting and radioimmunotherapy efficacy with an antibody targeting Prostate Specific Antigen Joanna Strand – Lund University
14.20 ABS 16	Evaluation of molecular design of HER2-targeting affibody-drug conjugates for drug delivery to ovarian cancer Tianqi Xu – Uppsala University
14.30 – 14.40	Short break
SESSION 5	INVITED SPEAKERS Moderator: Lovisa Lundholm – Stockholm University
14.40 – 15.20	An in-depth analysis of the anti-tumor immune response induced by radiation & CTLA-4 therapy Invited speaker: Dr. Nils Rudqvist, MD Anderson, Texas, USA
15.20 – 16.00	Alpha therapy in breast cancer Invited speaker: Dr. Sarah M Cheal, MSKCC, New York, USA
16.00 – 16.10	Short break
SESSION 6	RAPID FIRE Moderator: Anzhelika Vorobyeva – Uppsala University
16.10 ABS 17	Intratumoral distribution of ^{177}Lu -PSMA-617 over time and in comparison with ^{18}F -PSMA-1007 Anders Örbom – Lund University
16.20 ABS 18	HER3 PET-imaging using a ^{68}Ga -labeled affibody molecule provides favorable image contrast compared with ^{89}Zr -labeled antibody and F(ab')_2 -fragment based tracers Sara Rinne – Uppsala University
16.30 ABS 19	Characterization of a new panel of ^{89}Zr -labeled anti-RON monoclonal antibodies as a targeting agent for molecular imaging and cancer therapeutics Diana Spiegelberg – Uppsala University
16.40 ABS 20	New doctoral project on improving dosimetry for targeted alpha therapies Erik Leidermark – University of Gothenburg
16.50 – 17.00	CLOSING SECOND DAY

THU 10th June 2021	12.30 -17.00 Zoom link: https://stockholmuniversity.zoom.us/j/62820645913
12.30 12:45 ABS 4	ZOOM LINK OPENING – CHECK-IN A Phase II trial of ¹⁷⁷ Lu-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma, LuDO-N Jakob Stenman – Karolinska University Hospital and Karolinska Institutet
SESSION 7	RAPID FIRE Moderator: Bo Stenerlöv – Uppsala University
13.00 ABS 21	Cellular and gene expression changes in VH10 and AHH-1 cells after chronic and acute exposure to low doses of low, high and mixed LET ionizing radiation Milagrosa Lopez Riego – Stockholm University
13.10 ABS 22	High-yield synthesis of clinically relevant DOTA-based tracers using cyclotron-produced gallium-68 Emma Jussing – Karolinska Institutet
13.20 ABS 23	Combined treatment of mice bearing HER2-expressing xenografts by trastuzumab and Affibody-mediated PNA-based pretargeting improves their survival Maryam Oroujeni – Uppsala University
13.30 ABS 24	DOTA-conjugation and ¹⁷⁷ Lu-DOTA-radiolabeling optimizations of IgG4 antibodies Preeti Jha – Uppsala University
13.40 ABS 25	Impact of DOTA position on biodistribution of ¹⁷⁷ Lu-labelled ABD-fused Affibody molecules Yongsheng Liu – Uppsala University
13.50 – 13.55	Biobreak
SESSION 8	RAPID FIRE Moderator: Kristina Viktorsson – Karolinska Institutet
13.55 ABS 26	Selection of optimal radiolabel position and composition in DARPIn Ec1 for high-contrast imaging of EpCAM Expression in Prostate cancer Anzhelika Vorobyeva – Uppsala University
14.05 ABS 27	Development of ²¹¹ At and ¹²⁵ I Radiopharmaceuticals for Pretargeted Radioimmunotherapy of Disseminated Cancer Chiara Temperanza - University of Gothenburg
14.15 ABS 28	Monte Carlo simulated cell dosimetry for γ-H2AX foci distribution prediction in alpha particle irradiated cells Emma Mellhammar – Lund University
14.25 ABS 29	Cyclotron production of ⁶⁶ Ga for radiolabelling of nanoparticles for simultaneous detection using PET/MR Emmy Dalqvist – Karolinska Institutet
14.25-14.35	Short break
SESSION 9	INVITED SPEAKERS Moderator: Thuy Tran – Karolinska Institutet
14.35 – 15.05	PET/MR in the clinics: Possibilities and challenges Invited speaker: Prof. Håkan Ahlström, Uppsala University
15.05 – 16.05	Workshop: “What have we learnt & future directions” – Breakout session Moderators: Kristina Viktorsson – Karolinska Institutet Eva Forssell-Aronsson – University of Gothenburg
16.05 – 16.50	Immunotherapy and PET imaging Invited speaker: Prof. Elisabeth de Vries, University Medical Center Groningen, The Netherlands
16.50– 17.00	CLOSING OF THE MEETING Eva Forssell-Aronsson – University of Gothenburg

ZOOM-meeting guidelines: Please, mute yourself at all points when you are not presenting or given the word by the moderator to ask questions. Moderators, please mute your microphones during the presentations. If you have questions to the speakers, write them in the chat and we will give you the word to ask yourself or ask it for you as time permits. For the breakout sessions, we will put you in different ZOOM rooms automatically and take you back to a joint wrap-up. Thank you!